Omnicell, Inc. (OMCL) EVP Robin Gene Seim Sells 9,780 Shares of Stock
Omnicell, Inc. (NASDAQ:OMCL) EVP Robin Gene Seim sold 9,780 shares of the firm’s stock in a transaction dated Friday, September 15th. The shares were sold at an average price of $48.97, for a total value of $478,926.60. Following the completion of the transaction, the executive vice president now owns 55,896 shares of the company’s stock, valued at approximately $2,737,227.12. The sale was disclosed in a document filed with the SEC, which is available through this link.
Robin Gene Seim also recently made the following trade(s):
- On Tuesday, August 15th, Robin Gene Seim sold 15,109 shares of Omnicell stock. The shares were sold at an average price of $50.86, for a total value of $768,443.74.
Shares of Omnicell, Inc. (OMCL) traded down 1.11% during midday trading on Friday, reaching $49.10. 473,758 shares of the company’s stock traded hands. The stock has a 50-day moving average price of $50.08 and a 200 day moving average price of $43.42. The firm’s market cap is $1.84 billion. Omnicell, Inc. has a 12 month low of $30.35 and a 12 month high of $52.70.
Omnicell (NASDAQ:OMCL) last issued its quarterly earnings data on Thursday, July 27th. The company reported $0.02 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.02. Omnicell had a negative net margin of 1.14% and a positive return on equity of 0.41%. The business had revenue of $180.90 million during the quarter, compared to the consensus estimate of $174.08 million. During the same period in the prior year, the firm posted $0.38 EPS. The firm’s quarterly revenue was up 4.6% compared to the same quarter last year. Equities research analysts predict that Omnicell, Inc. will post $1.30 earnings per share for the current year.
Several institutional investors have recently added to or reduced their stakes in OMCL. BlackRock Inc. grew its position in shares of Omnicell by 139,475.2% during the 1st quarter. BlackRock Inc. now owns 4,487,343 shares of the company’s stock valued at $182,412,000 after acquiring an additional 4,484,128 shares during the period. Janus Henderson Group PLC grew its position in shares of Omnicell by 129.6% during the 2nd quarter. Janus Henderson Group PLC now owns 1,231,933 shares of the company’s stock valued at $53,096,000 after acquiring an additional 695,334 shares during the period. Principal Financial Group Inc. grew its position in shares of Omnicell by 124.9% during the 2nd quarter. Principal Financial Group Inc. now owns 660,803 shares of the company’s stock valued at $28,481,000 after acquiring an additional 367,019 shares during the period. Wells Fargo & Company MN grew its position in shares of Omnicell by 99.6% during the 1st quarter. Wells Fargo & Company MN now owns 561,295 shares of the company’s stock valued at $22,817,000 after acquiring an additional 280,017 shares during the period. Finally, Tributary Capital Management LLC bought a new position in shares of Omnicell during the 1st quarter valued at approximately $8,908,000. 96.35% of the stock is owned by hedge funds and other institutional investors.
A number of equities analysts recently commented on the company. Benchmark Co. lifted their price target on Omnicell from $55.00 to $67.00 and gave the stock a “buy” rating in a report on Tuesday, September 5th. BidaskClub cut Omnicell from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Piper Jaffray Companies reiterated a “hold” rating and set a $40.00 price target on shares of Omnicell in a report on Sunday, July 30th. Dougherty & Co lifted their price target on Omnicell from $45.00 to $49.00 and gave the stock a “buy” rating in a report on Friday, July 28th. Finally, Craig Hallum lifted their price target on Omnicell from $46.00 to $52.00 and gave the stock a “buy” rating in a report on Friday, July 28th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Omnicell has a consensus rating of “Buy” and an average target price of $51.57.
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with MarketBeat.com's FREE daily email newsletter.